

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR or BR are suitable (Managed access partial review of TA663) [ID6291]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Final appraisal determination**

(when no ACD was issued)

1.	Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
	None identified at scoping
2.	Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
	<b>UK CLL Forum &amp; British Society of Haematology:</b>  Difference in infrastructure between different NHS settings (tertiary centre vs district general setting).  Obinutuzumab intravenous administration carries a higher risk of infusion reaction and the need for medical intervention.  The set-up of the daycare unit in terms of proximity, opening times and ease of access to inpatient acute admission beds differs between NHS trusts –

reduced availability of daycare and inpatient beds may dissuade clinicians to use Ven+O.

These could be addressed within the recommendation for this technology evaluation.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
No

**Approved by Associate Director (name):** .....Lorna Dunning .....

**Date:** 04/12/2025